Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.6. MACD crossing signal line is bullish signal.
| MarketCap | 76.8B |
|---|---|
| PE Ratio | 37.7 |
| PEG Ratio | 3.0 |
| P/B | 21.5 |
| P/S (ttm) | 12.6 |
| Earning Growth (QoQ) | 32% |
| Revenue Growth (QoQ) | |
| Short % | 1% |
| Held by Institutions % | 94% |
| 1 Day Vol Adjusted Return | -0.2 |
| 1 Month Vol Adjusted Return | 8.6 |
| 3 Month Vol Adjusted Return | 3.7 |
| 6 Month Vol Adjusted Return | -4.6 |
| 20 Days SMA Price ZScore | 0.9 |
| 50 Days SMA Price ZScore | 1.7 |
| 12 -26 Days PPO | 2.9 |
| 1 Month Average Short Volume Ratio | 54.4 |
| 1 Day Volume Change ZScore | -0.8 |
| 1 Month Daily Vol | 1.7 |
Stock news
These businesses offer powerful passive income potential, growing their dividends between 178% and 481% over the last five years.
Zoetis (ZTS) closed at $165.18 in the latest trading session, marking a -1.82% move from the prior day.
UTHR vs. ZTS: Which Stock Is the Better Value Option?
Companies are reporting higher taxable income amid a change in tax law that affects how they treat spending on research and development.
When you're smooshing your dog's monthly heartworm pill into a dollop of peanut butter to make it more appetizing for Fido, there's a good chance that you're trying to get your pet to consume one of Zoetis' (NYSE: ZTS) products. Time was on your side if you bought shares of Zoetis in early 2013, right after its initial public offering (IPO). In short, your $5,000 investment in Zoetis from 10 years ago would now be worth just under $25,500, marking a gain of around 410%.
Whether you're a doting dog mom or a steely-eyed cattle rancher, you'll probably agree that animals need healthcare, just as we do. Enter Zoetis (NYSE: ZTS), a multinational pharmaceutical player that caters exclusively to developing medicines and other healthcare goods for pets and livestock. Thanks to its long history of developing and selling everything from pet pain pills to diagnostic hardware for veterinary clinics, this company has a lot to offer for investors of all stripes.
Shares of Zoetis (NYSE: ZTS) were losing ground in 2022 as the pet pharmacist saw headwinds related to a slowdown in the pet sector. A compression in valuations in growth stocks due to rising interest rates also led investors to move money into bonds and safer stocks. According to data from S&P Global Market Intelligence, the stock finished 2022 down 40%.
COLL vs. ZTS: Which Stock Is the Better Value Option?
Last year was an awful one for many growth stocks. Three stocks that struggled mightily last year that analysts think can soar include Zoetis (NYSE: ZTS), Amazon (NASDAQ: AMZN), and Take-Two Interactive (NASDAQ: TTWO). Last year was a brutal one for animal health company Zoetis as its shares dropped a staggering 40%.
Zoetis' business is generally stable and very consistent -- but the same can't be said for its struggling stock.